HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

Table 4 Comparison to RAMs combinations decreasing response to dolutegravir in the VIKING-3 study

RAMs combinations after RAL use	Prevalence (%)
RAMs combinations after RAL use	VIKING-3 [15]	This study
No INSTIs mutations	33	48
No Q148^a	36	40
Q148 + 1 secondary mutation^b	20	8
Q148 + ≥2 secondary mutations^b	11	4

RAMs resistance associated mutations, RAL raltegravir, INSTIs integrase strand transfer inhibitors
^aY143, N155, T66 or E92
^bG140A/C/S, L74I or E138A/K/T

ISSN: 1742-6405